Biofrontera Inc. Income Statement
BFRI|5 years of annual SEC 10-K data (FY2021-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Biofrontera Inc. reported $37M in revenue and $18M in net loss for FY2025. Revenue has grown at a 18.6% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $37.3M | $34.1M | $28.7M | $24.1M | $18.8M |
| SG&A Expense | $33.8M | $18.5M | $35.1M | $36.5M | $17.7M |
| R&D Expense | $2.1M | $77.0K | $77.0K | - | - |
| Operating Income | -$17.2M | -$22.7M | -$18.6M | -$25.2M | -$9.6M |
| Interest Expense | - | - | $12.0K | $344.0K | $2.9M |
| Income Tax | $22.0K | $14.0K | $32.0K | $56.0K | $64.0K |
| Net Income | -$17.8M | -$20.1M | -$640.0K | -$37.7M | -$11.0M |
| EPS (Basic) | -$3.22 | -$13.02 | -$0.61 | -$4.28 | - |
| EPS (Diluted) | -$3.22 | -$13.02 | -$0.61 | - | -$479.48 |
| Shares Outstanding | 8.9M | 1.5M | 1.3M | 855.2K | 8.0M |
| Operating Margin | -46.1% | -66.6% | -64.8% | -104.6% | -51.0% |
| Profit Margin | -47.6% | -59.1% | -2.2% | -156.5% | -58.3% |